Nathan K. Leclair

Nathan K. Leclair

Auto-generated profile, based on publicly available information

Nathan K. Leclair

MD/PhD Program, University of Connecticut School of Medicine, Farmington, CT, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2018 in WIREs RNA
Verified
Journal Article
Closed access
PDF file
LULaura M. Urbanski
Laura M. Urbanski
NLNathan Leclair
Nathan Leclair
OAOlga Anczukow
Olga Anczukow

10 November 2020 in Molecular Cell
Verified
Journal Article
Closed access
NLNathan K. Leclair
Nathan K. Leclair
MBMattia Brugiolo
Mattia Brugiolo
LULaura Urbanski
Laura Urbanski
SLShane C. Lawson
Shane C. Lawson
KTKetan Thakar
Ketan Thakar
OAOlga Anczukow
Olga Anczukow

1 November 2019 in Cell Reports
Verified
Journal Article
Open access
SPSungHee Park
SungHee Park
MBMattia Brugiolo
Mattia Brugiolo
MAMartin Akerman
Martin Akerman
SDShipra Das
Shipra Das
LULaura Urbanski
Laura Urbanski
OAOlga Anczukow
Olga Anczukow
Misregulation of alternative splicing is a hallmark of human tumors, yet to what extent and how it contributes to malignancy are only beginning to be unraveled. Here, we define which members of the splicing factor SR and SR-like families contribute to breast cancer and uncover differences and redundancies in their targets and biological functions. We identify splicing factors frequently altered in human breast tumors and assay their oncogenic functions using breast organoid models. We demonstrate that not all splicing factors affect mammary tumorigenesis in MCF-10A cells. Specifically, the upregulation of SRSF4, SRSF6, or TRA2β disrupts acinar morphogenesis and promotes cell proliferation and invasion in MCF-10A cells. By characterizing the targets of these oncogenic splicing factors, we identify shared spliced isoforms associated with well-established cancer hallmarks. Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.

22 November 2022 in Cell Reports
Verified
Journal Article
Open access
LULaura Urbanski
Laura Urbanski
MBMattia Brugiolo
Mattia Brugiolo
SPSungHee Park
SungHee Park
BABrittany L. Angarola
Brittany L. Angarola
NLNathan K. Leclair
Nathan K. Leclair
OAOlga Anczukow
Olga Anczukow
MYC is dysregulated in >50% of cancers, but direct targeting of MYC has been clinically unsuccessful. Targeting downstream MYC effector pathways represents an attractive alternative. MYC regulates alternative mRNA splicing, but the mechanistic links between MYC and the splicing machinery in cancer remain under-explored. Here, we identify a network of co-expressed splicing factors (SF-modules) in MYC-active breast tumors. Of these, one is a pan-cancer SF-module correlating with MYC activity across 33 tumor types. In mammary cell models, MYC activation leads to co-upregulation of pan-cancer module SFs and to changes in >4,000 splicing events. In breast cancer organoids, co-overexpression of the pan-cancer SF-module induces MYC-regulated splicing events and increases organoid size and invasiveness, while knockdown decreases organoid size. Finally, we uncover a MYC-activity pan-cancer splicing signature correlating with survival across tumor types. Our findings provide insight into the mechanisms of MYC-regulated splicing and for the development of therapeutics for MYC-driven tumors.

15 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NLNathan K. Leclair
Nathan K. Leclair
MBMattia Brugiolo
Mattia Brugiolo
SPSungHee Park
SungHee Park
MDMaeva Devoucoux
Maeva Devoucoux
LULaura Urbanski
Laura Urbanski
OAOlga Anczukow
Olga Anczukow
Upregulated expression of the oncogenic splicing factor TRA2β occurs in human tumors partly through decreased inclusion of its autoregulatory non-coding poison exon (PE). Here, we reveal that low TRA2β-PE inclusion negatively impacts patient survival across several tumor types. We demonstrate the ability of splice-switching antisense oligonucleotides (ASOs) to promote TRA2β-PE inclusion and lower TRA2β protein levels in pre-clinical cancer models. TRA2β-PE-targeting ASOs induce anti-cancer phenotypes and widespread transcriptomic alterations with functional impact on RNA processing, mTOR, and p53 signaling pathways. Surprisingly, the effect of TRA2β-PE-targeting ASOs on cell viability are not phenocopied by TRA2β knockdown. Mechanistically, we find that the ASO functions by both decreasing TRA2β protein and inducing the expression of TRA2β-PE-containing transcripts that act as long non-coding RNAs to sequester nuclear proteins. Finally, TRA2β-PE-targeting ASOs are toxic to preclinical 3D organoid and in vivo patient-derived xenograft models. Together, we demonstrate that TRA2β-PE acts both as a regulator of protein expression and a long-noncoding RNA to control cancer cell growth. Drugging oncogenic splicing factors using PE-targeting ASOs is a promising therapeutic strategy.

13 September 2024 in Science
Verified
Journal Article
Closed access
TKTimofey A. Karginov
Timofey A. Karginov
AMAntoine Ménoret
Antoine Ménoret
NLNathan K. Leclair
Nathan K. Leclair
AHAndrew G. Harrison
Andrew G. Harrison
KCKarthik Chandiran
Karthik Chandiran
AVAnthony T. Vella
Anthony T. Vella
T cell receptor (TCR) sensitivity to peptide–major histocompatibility complex (MHC) dictates T cell fate. Canonical models of TCR sensitivity cannot be fully explained by transcriptional regulation. In this work, we identify a posttranscriptional regulatory mechanism of TCR sensitivity that guides alternative splicing of TCR signaling transcripts through an evolutionarily ultraconserved poison exon (PE) in the RNA-binding protein (RBP) TRA2β in mouse and human. TRA2 β - PE splicing, seen during cancer and infection, was required for TCR-induced effector T cell expansion and function. Tra2 β-PE skipping enhanced T cell response to antigen by increasing TCR sensitivity. As antigen levels decreased, Tra2 β-PE reinclusion allowed T cell survival. Finally, we found that TRA2 β-PE was first included in the genome of jawed vertebrates that were capable of TCR gene rearrangements. We propose that TRA2 β - PE splicing acts as a gatekeeper of TCR sensitivity to shape T cell fate.